Supernus Pharmaceuticals Inc.
15 drugs in NADAC|0 Generic,15 Brand
Supernus Pharmaceuticals Inc. lists 15 NDCs in the CMS NADAC file (0 generic, 15 brand), at an average NADAC of $20.48 per unit, with a week-over-week move of +0.1% across products that moved. The firm's full portfolio, pricing trend are listed below.
Total Drugs
15
0G / 15B
Avg Price / Unit
$20.4819
$9.02 – $47.14
Avg 7d Change
+0.05%
Across 6 drugs with changes
7d Activity
of 15 total drugs
Portfolio Price Trend
Monthly average NADAC price across all drugs
Keep following this manufacturer
These next-step links connect the manufacturer page to the markets, classes, and trend views most likely to deepen research.
Lead market
topiramate market
See the molecule this manufacturer shows up in most often and compare it against competing suppliers.
Lead class
Norepinephrine Reuptake Inhibitor therapeutic class
Review the broader class where Supernus Pharmaceuticals Inc. has the strongest current portfolio footprint.
Trend hub
Portfolio trend view
Jump to the trend hub to compare this manufacturer against the rest of the market on weekly price movement.
Guide
NADAC pricing primer
Use the explainer for context on the benchmark this manufacturer is being compared against.
Frequently Asked Questions
How many drugs does Supernus Pharmaceuticals Inc. make?
Supernus Pharmaceuticals Inc. lists 15 NDCs in the CMS NADAC file — 0 generic and 15 brand products.
What is the average price of Supernus Pharmaceuticals Inc. drugs?
The average NADAC across Supernus Pharmaceuticals Inc.'s portfolio is $20.4819 per unit, ranging from $9.0247 to $47.1431.
What types of drugs does Supernus Pharmaceuticals Inc. make?
Supernus Pharmaceuticals Inc. makes drugs across 2 FDA pharmacologic classes. The most common by NDC count are Norepinephrine Reuptake Inhibitor (4), Anti-epileptic Agent (3).
Has Supernus Pharmaceuticals Inc. had any drug recalls?
No FDA enforcement recalls are matched to Supernus Pharmaceuticals Inc. in the openFDA feed.
How has Supernus Pharmaceuticals Inc.'s pricing changed recently?
Over the past 7 days, 2 Supernus Pharmaceuticals Inc. products rose and 4 fell, with a portfolio-wide average change of +0.1%.
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
TROKENDI XR 200 MG CAPSULE topiramate | $47.1431 per EA | — |
TROKENDI XR 200 MG CAPSULE topiramate | $41.4375 per EA | — |
TROKENDI XR 100 MG CAPSULE topiramate | $34.4376 per EA | — |
TROKENDI XR 100 MG CAPSULE topiramate | $30.3781 per EA | — |
OXTELLAR XR 600 MG TABLET OXCARBAZEPINE | $23.2989 per EA | +0.41% |
TROKENDI XR 50 MG CAPSULE topiramate | $17.4332 per EA | — |
TROKENDI XR 50 MG CAPSULE topiramate | $15.3195 per EA | — |
TROKENDI XR 25 MG CAPSULE topiramate | $13.2995 per EA | — |
OXTELLAR XR 300 MG TABLET OXCARBAZEPINE | $12.7521 per EA | +0.03% |
QELBREE ER 200 MG CAPSULE viloxazine hydrochloride | $12.7380 per EA | -0.02% |
QELBREE ER 200 MG CAPSULE viloxazine hydrochloride | $12.7380 per EA | -0.02% |
QELBREE ER 100 MG CAPSULE viloxazine hydrochloride | $12.7326 per EA | 0.00% |
QELBREE ER 150 MG CAPSULE viloxazine hydrochloride | $12.7310 per EA | -0.02% |
TROKENDI XR 25 MG CAPSULE topiramate | $11.7640 per EA | — |
OXTELLAR XR 150 MG TABLET OXCARBAZEPINE | $9.0247 per EA | -0.09% |